-
公开(公告)号：US20180327360A1
公开(公告)日：2018-11-15
申请号：US16041641
申请日：2018-07-20
发明人： Luca Gobbi , Uwe Grether , Matthias Nettekoven , Stephan Roever , Mark Rogers-Evans , Roger Slavik
IPC分类号： C07D213/81 , C07D491/10 , C07D417/12 , C07D417/06 , C07D413/12 , C07D401/04 , C07D417/14 , C07D413/14 , C07D405/14 , C07D401/14 , C07K5/078 , C07D491/107
CPC分类号： C07D213/81 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D491/10 , C07D491/107 , C07K5/06139
摘要： The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
-
公开(公告)号：US20180136298A1
公开(公告)日：2018-05-17
申请号：US15573284
申请日：2016-05-12
IPC分类号： G01R33/565 , G01R33/389 , G01R33/58 , G01R33/46
CPC分类号： G01R33/56518 , G01R33/389 , G01R33/4625 , G01R33/58
摘要： A method of determining an actual gradient impulse response function during execution of a magnetic resonance (MR) imaging or spectroscopy sequence, wherein a main magnetic field is generated in a sample region of an MR apparatus by means of a main magnet and wherein superimposed time dependent gradient fields and radiofrequency fields in a first RF band are generated in the sample region according to a first MR sequence for forming images or spectra, the gradient fields being generated by gradient forming means of the MR apparatus operated according to a gradient forming sequence part of said first MR sequence, the MR apparatus further comprising at least one magnetic field probe. The method comprises the steps of: —operating said at least one magnetic field probe according to a second sequence, whereby a time dependent probe signal is repeatedly acquired from each magnetic field probe during a probe acquisition time window, thus providing at least one time dependent probe signal; —obtaining said actual gradient impulse response function by calculating an impulse response function from said at least one time dependent probe signal and from said gradient forming sequence part.
-
3.发明申请公开(公告)号：US20020061288A1
公开(公告)日：2002-05-23
申请号：US10035625
申请日：2001-12-28
IPC分类号： A61K031/74 , A61L002/00 , A61K047/48 , B05D003/00
CPC分类号： A61L31/10 , A61L27/34 , A61L29/085 , C08L71/02
摘要： Boronic acid containing polymers are used to form bioinert gels and multilayer surface structures. These polymers form crosslinked hydrogels, which are highly swollen in water. The crosslinking can either be chemical or physical. Water soluble polymers containing boronic acid groups, such as phenylboronic acid (PBA), can be physically crosslinked by mixing the polymers in water with other polymers containing hydroxyls or carboxylic acids. Alternatively, surfaces can be treated by stepwise incubation with a solution of the boronic acid containing polymer, followed by incubation with a solution of a diol or carboxylic acid containing polymer. Many successive layers can be generated, increasing the thickness of the formed structure at each step. The bioinert gel or surface coating can be used for passivating the surfaces of medical implants (especially those based on transplanted tissue), or for passivating the surfaces of tissues in situ, decreasing the incidence or severity of such pathologic conditions as the formation of post-surgical adhesions, and thrombosis following angioplasty.
摘要翻译： 含硼酸的聚合物用于形成生物凝胶和多层表面结构。 这些聚合物形成在水中高度溶胀的交联水凝胶。 交联可以是化学或物理的。 含有硼酸基团的水溶性聚合物如苯基硼酸（PBA）可通过将水中的聚合物与含有羟基或羧酸的其它聚合物混合而物理交联。 或者，可以通过与含硼酸的聚合物的溶液逐步温育，然后与含二醇或含羧酸的聚合物的溶液温育来处理表面。 可以产生许多连续的层，从而在每个步骤增加形成的结构的厚度。 生物测定凝胶或表面涂层可用于钝化医疗植入物（特别是基于移植组织的植入物）的表面，或用于钝化组织表面的原位，降低这种病理状况的发生率或严重程度， 手术粘连和血管成形术后的血栓形成。
-
4.发明申请公开(公告)号：US20180172784A1
公开(公告)日：2018-06-21
申请号：US15577860
申请日：2016-05-30
IPC分类号： G01R33/28 , A61B34/20 , G01R33/565
CPC分类号： G01R33/287 , A61B34/20 , A61B2034/2051 , A61B2090/374 , A61B2090/502 , G01R33/56509
摘要： The invention relates to a system and a method for tracking position and orientation of an object in a magnetic resonance (MR) apparatus. The system comprises a tracking device for electromagnetic measurements of position and orientation with a) a tracker structure (2) that is firmly attachable to the object (4) of which the position and orientation are to be measured; b) retransmitter means (6; 8a, 8b, 8c) firmly attached to said tracker structure, said retransmitter means having at least one retransmitter resonance frequency; and c) electrical circuitry means including: i) transmitter means (10) for transmitting an electromagnetic field with at least one of said retransmitter resonance frequencies; ii) receiver means (12; 14a,14b) for receiving an electromagnetic field retransmitted by said retransmitter means; said receiver means converting said electromagnetic field into a proportional voltage; and iii) calculating means for determining, from said proportional voltages obtained from said receiver means, a position and orientation of said retransmitter means, and concomitantly of said object. The tracking device can be used in an operating MR imaging or spectroscopy apparatus.
-
公开(公告)号：US09307775B2
公开(公告)日：2016-04-12
申请号：US14017029
申请日：2013-09-03
发明人： Stefan Kappeler , Zakaria Farah , Johannes Maarten Van den Brink , Henrik Rahbek-Nielsen , Peter Budtz
CPC分类号： A23C19/043 , C12N9/6483 , C12Y304/23004
摘要： A method of recombinantly producing a non-bovine pre-prochymosin, prochymosin or chymosin derived from ruminant species including deer species, buffalo species, antelope species, giraffe species, ovine species and caprine species; Camelidae species such as Camelus dromedarius; porcine species; or Equidae species. The recombinant enzymes are used in milk coagulating compositions in cheese manufacturing based on cow's milk and milk from any animal species which are used in cheese manufacturing including camel's milk.
摘要翻译： 一种重组产生源自鹿类，水牛种，羚羊种，长颈鹿物种，羊种和山羊种的反刍动物物种的非牛前凝乳酶原，凝乳酶原或凝乳酶的方法; 骆驼科（Camelidae）种如骆驼属骆驼属（Camelus dromedarius）; 猪种; 或Equidae种。 重组酶用于奶酪制造中的牛奶凝固组合物，其基于来自用于奶酪制造的任何动物物种的牛奶和牛奶，包括骆驼乳。
-
公开(公告)号：US20150154889A1
公开(公告)日：2015-06-04
申请号：US14616409
申请日：2015-02-06
摘要： Simulation systems and methods may enable virtual imaging. A data processing unit may receive data from a calibration unit indicating a position and/or orientation of a position and orientation sensor relative to a physical model. The data processing unit may also receive data from the position and orientation sensor indicating a position and/or orientation of the physical model. The data processing unit may generate a virtual image using the data from the position and orientation sensor and the data from the calibration unit. The data processing unit may render the virtual image to a display.
摘要翻译： 仿真系统和方法可以实现虚拟成像。 数据处理单元可以从校准单元接收指示相对于物理模型的位置和方向传感器的位置和/或取向的数据。 数据处理单元还可以从位置和方向传感器接收指示物理模型的位置和/或取向的数据。 数据处理单元可以使用来自位置和方向传感器的数据和来自校准单元的数据来生成虚拟图像。 数据处理单元可以将虚拟图像呈现给显示器。
-
公开(公告)号：US20030166833A1
公开(公告)日：2003-09-04
申请号：US10325021
申请日：2002-12-18
IPC分类号： A61K038/00 , C07K014/00
CPC分类号： A61L27/225 , A61K38/00 , A61L27/227 , C07K14/635 , C07K2319/00
摘要： Proteins are incorporated into protein or polysaccharide matrices for use in tissue repair, regeneration and/or remodeling and/or drug delivery. The proteins can be incorporated so that they are released by degradation of the matrix, by enzymatic action and/or diffusion. As demonstrated by the examples, one method is to bind heparin to the matrix by either covalent or non-covalent methods, to form a heparin-matrix. The heparin then non-covalently binds heparin-binding growth factors to the protein matrix. Alternatively, a fusion protein can be constructed which contains a crosslinking region such as a factor XIIIa substrate and the native protein sequence. Incorporation of degradable linkages between the matrix and the bioactive factors can be particularly useful when long-term drug delivery is desired, for example in the case of nerve regeneration, where it is desirable to vary the rate of drug release spatially as a function of regeneration, e.g. rapidly near the living tissue interface and more slowly farther into the injury zone. Additional benefits include the lower total drug dose within the delivery system, and spatial regulation of release which permits a greater percentage of the drug to be released at the time of greatest cellular activity.
-
8.发明申请Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides 失效用于组织工程的酶介导的纤维蛋白修饰：具有肽的纤维蛋白制剂公开(公告)号：US20030119186A1
公开(公告)日：2003-06-26
申请号：US10106804
申请日：2002-03-25
IPC分类号： C12N005/00 , C07K014/745
CPC分类号： C07K14/75 , A61L26/0042 , C12N5/0068 , C12N5/0619 , C12N2501/91 , C12N2533/56
摘要： Heparin-binding regions of several proteins, such as neural cell adhesion molecule, fibronectin, laminin, midkine, and anti-thrombin III have been shown to promote neurite extension on two-dimensional surfaces. The effect of heparin-binding peptides on neurite extension through three-dimensional matrices was investigated by culturing embryonic chick dorsal root ganglia (DRG) within fibrin gels containing chemically attached heparin-binding peptide (HBP). The length of neurites within fibrin gels containing cross-linked HBP was increased by more than 70% over extension through fibrin gels containing no peptide. The HBP sequence of antithrombin III was incorporated into the fibrin gel as the C-terminal domain of a bidomain, chimeric peptide; the N-terminal second domain of this peptide contained the null2-plasmin inhibitor substrate for Factor XIIIa. Factor XIIIa, a transglutaminase, was used to chemically attach the HBP-containing chimeric peptide to the fibrin gels during polymerization. The amount of HBP cross-linked into the fibrin gels was determined, after degradation by plasmin using gel permeation chromatography, to be approximately 8 moles of peptide per mole fibrinogen. A peptide (HBP), where the cross-linking glutamine was replaced with glycine, showed no increase in extension in comparison with fibrin gels. The addition of heparin to the gel precursors resulted in no increase in neurite extension in comparison with fibrin gels. HBPs promote neurite extension by binding to cell surface proteoglycans on the DRG.
摘要翻译： 几种蛋白质的肝素结合区域，例如神经细胞粘附分子，纤连蛋白，层粘连蛋白，中期因子和抗凝血酶III已被证明可促进二维表面的神经突延伸。 通过在包含化学连接的肝素结合肽（HBP）的纤维蛋白凝胶内培养胚胎小鸡背根神经节（DRG），研究肝素结合肽对通过三维基质的神经突延伸的作用。 含有交联HBP的纤维蛋白凝胶中的神经突的长度比通过不含肽的纤维蛋白凝胶延长超过70％。 抗凝血酶III的HBP序列被掺入纤维蛋白凝胶中，作为一个投标蛋白嵌合肽的C-末端结构域; 该肽的N末端第二结构域含有因子XIIIa的α2-纤溶酶抑制剂底物。 在聚合期间，使用因子XIIIa，转谷氨酰胺酶将含HBP的嵌合肽化学连接到纤维蛋白凝胶上。 在使用凝胶渗透色谱法的纤溶酶降解之后，测定交联到纤维蛋白凝胶中的HBP的量为每摩尔纤维蛋白原约8摩尔肽。 交联谷氨酰胺被甘氨酸取代的肽（HBP）与纤维蛋白凝胶相比显示延长不增加。 与纤维蛋白凝胶相比，向凝胶前体添加肝素导致神经突延伸不增加。 HBP通过与DRG上的细胞表面蛋白聚糖结合来促进神经突延伸。
-
公开(公告)号：US20030012818A1
公开(公告)日：2003-01-16
申请号：US10132619
申请日：2002-04-25
IPC分类号： A61K038/18 , A61K009/14
CPC分类号： A61L31/046 , A61L24/0015 , A61L24/106 , A61L27/225 , A61L27/227 , A61L27/54 , A61L2300/236 , A61L2300/252 , A61L2300/412 , A61L2300/414 , A61L2300/45
摘要： Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGFnull superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.
摘要翻译： 生物活性分子被包埋在基质内，用于受控递送这些化合物用于治疗性愈合应用。 基质可以由天然或合成的化合物形成。 捕获生物活性分子的主要方法是通过体外或体内在基质凝胶化过程中沉淀生物活性分子。 可以修饰生物活性分子以降低其在基质中的有效溶解度，从而更有效地将其保留在基质内，例如通过胱氨酸结生长因子超家族内，特别是在TGFbeta超家族内的成员的去糖基化。 可以修饰基质以包括对不同生物活性分子具有结合亲和力的位点，例如用于肝素结合的位点。
-
公开(公告)号：US20220374649A1
公开(公告)日：2022-11-24
申请号：US17484681
申请日：2021-09-24
发明人： Jacek Krzysztof NARUNIEC , Derek Edward BRADLEY , Paulo Fabiano Urnau GOTARDO , Leonhard Markus HELMINGER , Christopher Andreas OTTO , Christopher Richard SCHROERS , Romann Matthew WEBER
摘要： Various embodiments set forth systems and techniques for changing a face within an image. The techniques include receiving a first image including a face associated with a first facial identity; generating, via a machine learning model, at least a first texture map and a first position map based on the first image; rendering a second image including a face associated with a second facial identity based on the first texture map and the first position map, wherein the second facial identity is different from the first facial identity.
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.016 秒)